Revolutionary Robotic Heart Valve Replacement Procedure Marks a New Era in Cardiac Surgery

A Revolutionary Step in Cardiac Surgery

In a groundbreaking advancement for heart surgery, Corcym has announced the successful use of its Perceval Plus® sutureless aortic heart valve in the world’s first robotic aortic valve replacement. This significant milestone in cardiac care was performed by Dr. Marijan Koprivanac, a cardiovascular surgeon at Cleveland Clinic's Heart, Vascular & Thoracic Institute, through a small incision in the neck of a patient, marking a pivotal moment for minimally invasive heart surgery.

The procedure was made possible through an innovative integration of Corcym's artificial heart valve with CardioPrecision's CoreVista® Robot Enabling Platform. This combination not only represents an advanced surgical procedure—termed AVATAR (Advanced Videoscopic Aortic valve surgery by Transcervical Approach using Robot assistance)—but also the future of cardiac surgery, emphasizing the reduction of patient trauma and recovery times.

Dr. Christian Mazzi, CEO of Corcym, expressed his enthusiasm about this development, stating, "This pioneering surgical procedure strengthens our foothold in robotic surgery. By having our sutureless valve technology be used in this way, we helped to create a new option for robotic cardiac surgery." This statement highlights the transformative impact of robotic technology on cardiac procedures and how it can redefine surgical norms.

In discussing patient outcomes, Dr. Koprivanac highlighted, "Combining the artificial heart valve with this new surgical technology means patients should experience less pain and shorter hospital stays following heart surgery." He indicated that this technique may indeed be one of the least invasive surgical options currently available for heart valve replacement, representing a significant leap in patient-centered care.

The CoreVista® platform by CardioPrecision was mentioned as a game-changer in the realm of robotic-assisted surgeries, which are already widely adopted in various other surgical specialties. Dr. Fraser Sutherland, Chief Medical Officer of CardioPrecision, remarked, "Now cardiac surgeons can offer patients this least invasive option using robotics with our innovative CoreVista® platform, while ensuring their safety remains paramount."

This development not only emphasizes the need for innovation in cardiac procedures but also puts patient welfare at the forefront. As healthcare continually evolves, advanced solutions like the ones from Corcym and CardioPrecision reflect a commitment to improving surgical outcomes and enhancing the quality of life for patients suffering from structural heart diseases.

About CardioPrecision Ltd
Based in Glasgow, UK, CardioPrecision Ltd is a leader in transcervical access methods for treating structural heart diseases. Their commitment to innovation has dedicated its efforts to developing less invasive solutions for cardiothoracic surgery. For more information, visit CardioPrecision.com.

About Corcym
Corcym stands as the only global medical device company entirely focused on supporting cardiac surgeons with best-in-class solutions for managing structural heart diseases. With decades of trusted partnerships and a comprehensive product portfolio, Corcym provides innovative technologies to enhance surgical repair and replacement options in both open-heart and minimally invasive techniques. For further details, visit Corcym.com.

This announcement not only signifies the advancements achieved in robotic cardiac surgery but poses essential questions about the future of surgical practices and how they can align with patient-centered care. As technology and medicine converge, the potential for groundbreaking advances continues to rise, promising a future where surgeries are less daunting and recovery is swift, making thorough innovations in heart care a matter of urgency.